• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用可动员铁储存和酒精摄入量对HFE血色素沉着症患者的肝硬化和肝细胞癌进行风险评估

Risk profiling for cirrhosis and hepatocellular carcinoma in HFE hemochromatosis using mobilizable iron stores and alcohol consumption.

作者信息

Mitchell Natasha D P, Pierre Timothy G St, Ramm Louise E, Ramm Grant A, Olynyk John K

机构信息

Department of Gastroenterology, Fiona Stanley Hospital, Murdoch, WA, Australia.

School of Physics, Mathematics, and Computing, The University of Western Australia, Perth, WA, Australia.

出版信息

Sci Rep. 2025 May 8;15(1):16011. doi: 10.1038/s41598-025-99672-8.

DOI:10.1038/s41598-025-99672-8
PMID:40341892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12062215/
Abstract

HFE hemochromatosis (HH) may cause cirrhosis and hepatocellular carcinoma (HCC). Progression to these endpoints depends on the severity of iron overload and cofactors, such as alcohol. We evaluated alcohol and iron-related risk factors in relation to cirrhosis at diagnosis and future development of HCC in a retrospective analysis of 197 HH subjects. The proportion of subjects either with cirrhosis or who developed HCC during follow-up were 29/197 (14.7%) or 10/197 (5.1%), respectively. The median (IQR) follow-up time after diagnosis was 15.2 (4.6 to 22.1) years. The median mobilizable iron stores and daily alcohol consumption (IQR) were 6.0 (3.8-11.0) g and 20 (0-40) g, respectively. An optimal logistic regression model for the odds of cirrhosis was developed by adding candidate liver insult variables (mobilizable iron, alcohol consumption, and age as a surrogate for duration of exposure) in a forward stepwise strategy using area under the receiver operating characteristic curve (AUROC) analysis and the corrected Akaike information criterion. This model demonstrated an AUROC (95% CI) of 0.966 (0.935-0.996), with sensitivity 76 (58-88)% and specificity 97 (93-99) % for prediction of cirrhosis and had a negative predictive value of 99.4 (95% CI 96.7-99.97) % for development of HCC. Thus, future risk of HCC can be assessed from mobilizable iron stores and alcohol consumption of HH subjects.

摘要

HFE 遗传性血色素沉着症(HH)可能导致肝硬化和肝细胞癌(HCC)。疾病进展至这些终点取决于铁过载的严重程度以及酒精等辅助因素。我们在一项对 197 名 HH 受试者的回顾性分析中,评估了与诊断时的肝硬化以及未来 HCC 发生相关的酒精和铁相关危险因素。随访期间出现肝硬化或发生 HCC 的受试者比例分别为 29/197(14.7%)和 10/197(5.1%)。诊断后的中位(四分位间距)随访时间为 15.2(4.6 至 22.1)年。可动员铁储存量的中位数和每日酒精摄入量(四分位间距)分别为 6.0(3.8 - 11.0)克和 20(0 - 40)克。通过在前向逐步策略中添加候选肝脏损伤变量(可动员铁、酒精摄入量以及作为暴露持续时间替代指标的年龄),利用受试者工作特征曲线下面积(AUROC)分析和校正后的赤池信息准则,建立了一个关于肝硬化发生几率的最佳逻辑回归模型。该模型预测肝硬化的 AUROC(95%可信区间)为 0.966(0.935 - 0.996),敏感性为 76(58 - 88)%,特异性为 97(93 - 99)%,对 HCC 发生的阴性预测值为 99.4(95%可信区间 96.7 - 99.97)%。因此,可以根据 HH 受试者的可动员铁储存量和酒精摄入量来评估未来发生 HCC 的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b28/12062215/53a58c680633/41598_2025_99672_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b28/12062215/31e6e1122afe/41598_2025_99672_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b28/12062215/4dca6b086107/41598_2025_99672_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b28/12062215/53a58c680633/41598_2025_99672_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b28/12062215/31e6e1122afe/41598_2025_99672_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b28/12062215/4dca6b086107/41598_2025_99672_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b28/12062215/53a58c680633/41598_2025_99672_Fig3_HTML.jpg

相似文献

1
Risk profiling for cirrhosis and hepatocellular carcinoma in HFE hemochromatosis using mobilizable iron stores and alcohol consumption.利用可动员铁储存和酒精摄入量对HFE血色素沉着症患者的肝硬化和肝细胞癌进行风险评估
Sci Rep. 2025 May 8;15(1):16011. doi: 10.1038/s41598-025-99672-8.
2
Utility of hepatic or total body iron burden in the assessment of advanced hepatic fibrosis in HFE hemochromatosis.肝铁或全身铁负荷在 HFE 血色病中评估晚期肝纤维化的效用。
Sci Rep. 2019 Dec 27;9(1):20234. doi: 10.1038/s41598-019-56732-0.
3
HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence.肝细胞癌中HFE C282Y杂合性:患病率增加的证据。
Clin Gastroenterol Hepatol. 2003 Jul;1(4):279-84. doi: 10.1016/s1542-3565(03)00132-0.
4
Iron overload and HFE gene mutations in Polish patients with liver cirrhosis.波兰肝硬化患者的铁过载和 HFE 基因突变。
Hepatobiliary Pancreat Dis Int. 2011 Jun;10(3):270-5. doi: 10.1016/s1499-3872(11)60045-3.
5
Iron, hemochromatosis, and hepatocellular carcinoma.铁、血色素沉着症与肝细胞癌。
Gastroenterology. 2004 Nov;127(5 Suppl 1):S79-86. doi: 10.1016/j.gastro.2004.09.019.
6
Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis.肝硬化患者的肝脏铁、HFE基因突变与肝细胞癌的发生
Gastroenterology. 2008 Jan;134(1):102-10. doi: 10.1053/j.gastro.2007.10.038. Epub 2007 Oct 26.
7
Abdominal pain and cirrhosis at diagnosis of hemochromatosis: Analysis of 219 referred probands with HFE p.C282Y homozygosity and a literature review.遗传性血色病诊断时的腹痛和肝硬化:219 例 HFE p.C282Y 纯合子患者的分析及文献复习。
PLoS One. 2021 Dec 21;16(12):e0261690. doi: 10.1371/journal.pone.0261690. eCollection 2021.
8
Utility of Serum Biomarker Indices for Staging of Hepatic Fibrosis Before and After Venesection in Patients With Hemochromatosis Caused by Variants in HFE.铁调素基因突变所致血色病患者静脉放血前后血清标志物指标对肝纤维化分期的价值。
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1459-1468.e5. doi: 10.1016/j.cgh.2020.07.052. Epub 2020 Aug 1.
9
Regression of Fibrosis Stage With Treatment Reduces Long-Term Risk of Liver Cancer in Patients With Hemochromatosis Caused by Mutation in HFE.治疗逆转纤维化分期可降低 HFE 基因突变所致血色病患者的肝癌长期风险。
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1851-1857. doi: 10.1016/j.cgh.2019.10.010. Epub 2019 Oct 14.
10
Cirrhosis in Hemochromatosis: Independent Risk Factors in 368 HFE p.C282Y Homozygotes.血色病中的肝硬化:368 名 HFE p.C282Y 纯合子的独立危险因素。
Ann Hepatol. 2018 Aug 24;17(5):871-879. doi: 10.5604/01.3001.0012.3169.

本文引用的文献

1
Extrahepatic Iron Loading Associates With the Propensity to Develop Advanced Hepatic Fibrosis in Hemochromatosis.肝外铁负荷与血色素沉着症发生晚期肝纤维化的倾向相关。
Gastro Hep Adv. 2024 Jan 24;3(4):454-460. doi: 10.1016/j.gastha.2024.01.011. eCollection 2024.
2
Hemochromatosis.血色素沉着症
N Engl J Med. 2022 Dec 8;387(23):2159-2170. doi: 10.1056/NEJMra2119758.
3
Utility and limitations of Hepascore and transient elastography to detect advanced hepatic fibrosis in HFE hemochromatosis.Hepascore和瞬时弹性成像在检测HFE血色素沉着症患者晚期肝纤维化中的应用及局限性
Sci Rep. 2021 Jul 19;11(1):14654. doi: 10.1038/s41598-021-94083-x.
4
Association of Hemochromatosis HFE p.C282Y Homozygosity With Hepatic Malignancy.血色病 HFE p.C282Y 纯合子与肝恶性肿瘤的关联。
JAMA. 2020 Nov 24;324(20):2048-2057. doi: 10.1001/jama.2020.21566.
5
Utility of Serum Biomarker Indices for Staging of Hepatic Fibrosis Before and After Venesection in Patients With Hemochromatosis Caused by Variants in HFE.铁调素基因突变所致血色病患者静脉放血前后血清标志物指标对肝纤维化分期的价值。
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1459-1468.e5. doi: 10.1016/j.cgh.2020.07.052. Epub 2020 Aug 1.
6
Utility of hepatic or total body iron burden in the assessment of advanced hepatic fibrosis in HFE hemochromatosis.肝铁或全身铁负荷在 HFE 血色病中评估晚期肝纤维化的效用。
Sci Rep. 2019 Dec 27;9(1):20234. doi: 10.1038/s41598-019-56732-0.
7
Regression of Fibrosis Stage With Treatment Reduces Long-Term Risk of Liver Cancer in Patients With Hemochromatosis Caused by Mutation in HFE.治疗逆转纤维化分期可降低 HFE 基因突变所致血色病患者的肝癌长期风险。
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1851-1857. doi: 10.1016/j.cgh.2019.10.010. Epub 2019 Oct 14.
8
Developing prediction models for clinical use using logistic regression: an overview.使用逻辑回归开发临床应用的预测模型:综述
J Thorac Dis. 2019 Mar;11(Suppl 4):S574-S584. doi: 10.21037/jtd.2019.01.25.
9
Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank.与遗传性血色素沉着症遗传变异相关的常见病症:英国生物库队列研究。
BMJ. 2019 Jan 16;364:k5222. doi: 10.1136/bmj.k5222.
10
Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study.监测可提高肝细胞癌患者的生存率:一项前瞻性基于人群的研究。
Med J Aust. 2018 Oct 15;209(8):348-354. doi: 10.5694/mja18.00373.